Research programme: Streptococcus pneumoniae vaccine - Zymenex

Drug Profile

Research programme: Streptococcus pneumoniae vaccine - Zymenex

Alternative Names: ACE 720

Latest Information Update: 04 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACE BioSciences
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Streptococcal infections

Most Recent Events

  • 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
  • 06 Mar 2008 Preclinical development is ongoing
  • 10 May 2005 Streptococcus pneumoniae vaccine is available for licensing worldwide (http://www.acebiosciences.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top